Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06327685
Status:
RECRUITING
Last Update Posted:
2024-04-09
First Post:
2024-03-18
Brief Title:
Avapritinib With Decitabine in Patients With SM-AHN
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm SM-AHN
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Systemic mastocytosis with an associated hematologic neoplasm SM-AHN is a challenging disease to treat Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease but patients frequently experience progression of the concomitant myeloid malignancy ie the AHN Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control however overlapping toxicity is a concern In this study investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None